NSBP1 antibody - middle region (ARP37788_P050)
- Known as:
- NSBP1 (anti-) - middle region (ARP37788_P050)
- Catalog number:
- arp37788_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- NSBP1 antibody - middle region (ARP37788_P050)
Related genes to: NSBP1 antibody - middle region (ARP37788_P050)
- Gene:
- HMGN5 NIH gene
- Name:
- high mobility group nucleosome binding domain 5
- Previous symbol:
- NSBP1
- Synonyms:
- -
- Chromosome:
- Xq21.1
- Locus Type:
- gene with protein product
- Date approved:
- 2000-04-03
- Date modifiied:
- 2016-10-05
Related products to: NSBP1 antibody - middle region (ARP37788_P050)
Related articles to: NSBP1 antibody - middle region (ARP37788_P050)
- Group 3 (G3) is one of the most common and aggressive subtypes of the paediatric cerebellar tumour Medulloblastoma (MB), primarily driven by the MYC oncogene. The challenging targeting of MYC, coupled with gaps in understanding G3 MB molecular bases, has hindered the development of targeted therapies. The unconventional oncogenic roles of long noncoding RNAs (lncRNAs) offer opportunities to address this complexity, to provide insights and to identify novel targets. Using -omics approaches and molecular/cellular assays, we elucidate the mode-of-action of lncMB3, a MYC-dependent, anti-apoptotic lncRNA in G3 MB. LncMB3 regulates the TGF-β pathway, critically altered in G3 medulloblastomagenesis, via direct binding and translational inhibition of the mRNA for the epigenetic factor HMGN5. This regulatory axis affects apoptosis through photoreceptor lineage genes, including the G3 driver OTX2. The synergistic effects between lncMB3 targeting and cisplatin treatment underscore the relevance of this network. Additionally, we propose novel ferritin-based nanocarriers for the efficient delivery of antisense oligonucleotides against lncMB3. LncMB3 crucially links MYC amplification and apoptosis inhibition through a circuit involving RNA-based mechanisms, G3 MB key determinants and underexplored factors. This integrated framework deepens the understanding of G3 MB landscape and supports the potential for translating lncRNA research into future applications. - Source: PubMed
Publication date: 2025/11/06
Grandioso AlessiaTollis PaoloPellegrini Francesca RomanaFalvo ElisabettaPalma AlessandroMigliaccio FrancescoBelvedere AlessandroRea JessicaTisci GiadaCarissimo AnnamariaBozzoni IreneTrisciuoglio DanielaBallarino MonicaCeci PierpaoloLaneve Pietro - The role of autoantibodies in the pathogenesis of Multiple Sclerosis (MS) remains incompletely understood. In this study, we analysed serum samples from a cohort of MS patients in Qatar using high-throughput KoRectly Expressed (KREX) immunome protein-array technology. Compared to healthy controls, MS patients showed significantly altered autoantibody responses to 129 proteins, with a notable enrichment in autoantibodies targeting antiviral immune response-related proteins and oligodendrocyte marker SOX-10. Machine learning analysis identified a distinct molecular signature comprising 17 differentially expressed autoantibodies, including those against MX1, ISG20, MAX, SUFU, NR1H2, HMGN5, and EPHA10. Among these, autoantibodies against MX1-a key effector in the interferon-alpha/beta signalling pathway-showed the most pronounced increase, with nearly a threefold elevation in MS patients. While MX1 has previously been implicated in MS, this is the first report of autoantibody reactivity against the protein, suggesting a potential role in disease onset and progression. These findings support a link between antiviral immune responses and MS pathophysiology and offer a promising blood-based autoantibody signature that could inform future diagnostic and therapeutic strategies. - Source: PubMed
Publication date: 2025/09/30
Abdesselem Houaride la Fuente AlbertoBensmail IlhamElbashir Israa EAnuar DianaTi-Myen TanAbylova BermetBlackburn Jonathan MMalik Rayaz APetropoulos Ioannis N - Circular RNAs (circRNAs) are critical regulators in tumorigenesis, functioning as microRNA sponges or protein decoys. Although numerous circRNAs have been implicated in gastric cancer progression, the role of hsa_circRNA_101996 remains unclear. This study hypothesizes that hsa_circRNA_101996 promotes gastric cancer cell proliferation and apoptosis the microRNA-577 (miR-577)/high mobility group nucleosome binding domain 5 (HMGN5) axis. - Source: PubMed
Wang Xiao-LeiZhang LinShang Qing - This study aimed to identify and validate novel autoantibodies that reflect global and organ-specific disease activity in systemic lupus erythematosus (SLE). - Source: PubMed
Publication date: 2025/05/09
Lindblom JuliusLagutkin DenisSherina NataliaIdborg HelenaBeretta LorenzoBorghi Maria Orietta Peyper Janique MBarturen GuillermoJakobsson Per-JohanAlarcón-Riquelme Marta ENikolopoulos DionysisParodis Ioannis - The rational design of multifunctional drug delivery systems capable of achieving precise drug release remains a huge challenge. Herein, we designed a stimuli-responsive dendritic-DNA-based nanohydrogel as a nanocarrier to achieve the co-delivery of doxorubicin and mRNA-targeting antisense oligonucleotides, thus achieving dual therapeutic effects. The nanocarrier, constructed from dendritic DNA with three crosslinking branches and one loading branch, formed biocompatible and programmable DNA nanohydrogels. The C-rich sequences in the crosslinking branches conferred pH sensitivity, while the loading strand enabled efficient incorporation of a shielding DNA/ASO complex. DOX encapsulation yielded a chemo-gene co-delivery platform. Upon cellular uptake by cancer cells, the nanocarrier disassembled in the acidic tumor microenvironment, releasing DOX for chemotherapy and ASOs via toehold-mediated strand displacement (TMSD) for targeted gene silencing. Cellular studies demonstrated significantly enhanced cancer cell inhibition compared to single-agent treatments, highlighting strong combined effects. This study provides a novel strategy for tumor-microenvironment-responsive co-delivery, enabling precise, on-demand release of therapeutic agents to enhance combined chemo-gene therapy. - Source: PubMed
Publication date: 2025/04/06
Zhao JingWu JingyuanFan YiqiYu ChaoYu LeShao Fangwei